Drug Profile

Research programme: cancer vaccines - Vedantra Pharmaceuticals/BioNTech

Latest Information Update: 28 Apr 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Neon Therapeutics; Vedantra Precision Immunity
Developer BioNTech; Vedantra Precision Immunity
Class Antigens; Antineoplastics; Cancer vaccines; Conjugate vaccines; Immunoconjugates; Peptide vaccines
Mechanism of Action CD8 positive T lymphocyte modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

28 Apr 2021 No recent reports of development identified for research development in Cancer in USA (Parenteral, Injection)
06 May 2020 Neon Therapeutics has been acquired and merged into BioNTech
31 Oct 2017 Vedantra Pharmaceuticals and Neon Therapeutics extend collaboration for development of neo-antigen cancer vaccines

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com